Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423243 | 1.00 | LMNA (0.49) | LMNAMEN1KMT2AKITPOLB | |
| SCHEMBL6555717 | 0.85 | CA12 (0.54) | LMNAMEN1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL6555720 | 0.85 | CA12 (0.54) | LMNAMEN1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL4424646 | 0.84 | TSHR (0.43) | LMNAMEN1KMT2AKITCACNA1F | |
| SCHEMBL4424648 | 0.84 | TSHR (0.43) | LMNAMEN1KMT2AKITCACNA1F | |
| SCHEMBL4418504 | 0.83 | MMP8 (0.45) | LMNAMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4418506 | 0.83 | MMP8 (0.45) | LMNAMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23368101 | 0.83 | MEN1 (0.54) | LMNAMEN1KMT2ACA1CA2 | |
| SCHEMBL6507221 | 0.83 | MEN1 (0.54) | LMNAMEN1KMT2ACA1CA2 | |
| SCHEMBL3892343 | 0.83 | MEN1 (0.54) | LMNAMEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399628-B1 | ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2002-06-04 | — | — | US | claimed |
| JP-2001508408-A | — | — | 2001-06-26 | — | — | JP | claimed |
| US-5965614-A | A PEPTIDE BLOCKING AGENT FOR TREATING ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 1999-10-12 | — | — | US | claimed |
| EP-0944580-A2 | N-(ARYL/HETEROARYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998022441-A2 | N-(ARYL/HETEROARYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0951466-B1 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | THORSETT EUGENE D | 2007-08-30 | — | — | US | disclosed |
| US-7153847-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060079499-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING | 2006-04-13 | — | — | US | disclosed |
| US-20050272666-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING | 2005-12-08 | — | — | US | disclosed |
| US-20050215541-A1 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ATHENA NEUROSCIENCES, INC. AND ELI LILLY & COMPANY | 2005-09-29 | — | — | US | disclosed |
| US-20020055500-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-05-09 | — | — | US | disclosed |
| US-20020052359-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020045747-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-04-18 | — | — | US | disclosed |
| EP-0951466-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5965614-A | A PEPTIDE BLOCKING AGENT FOR TREATING ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 1999-10-12 | — | — | US | disclosed |
| EP-0944580-A2 | N-(ARYL/HETEROARYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998028268-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998022441-A2 | N-(ARYL/HETEROARYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055500-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | LMNA 1017/4885MEN1 1053/4885KMT2A 4758/4885 |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | APP, BACE1, PSEN1 | LMNA 2174/4885MEN1 1839/4885KMT2A 3421/4885 |
| US-20020045747-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | LMNA 1339/4885MEN1 953/4885KMT2A 4751/4885 |
| US-20050272666-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | LMNA 1272/4885MEN1 1035/4885KMT2A 4749/4885 |
| US-20060079499-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | LMNA 1272/4885MEN1 1035/4885KMT2A 4749/4885 |
| US-20050215541-A1 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | BACE1, APP, BACE2 | LMNA 1272/4885MEN1 1035/4885KMT2A 4749/4885 |
| US-20020052359-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | LMNA 1017/4885MEN1 1053/4885KMT2A 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.